Analysis of serum homocysteine levels in patients with colorectal cancer

( views:264, downloads:0 )
Author:
ZHANG Ying-lan(Department of Medical Laboratory,Shanxi Cancer Hospital,Taiyuan 030013,China)
SHI Hong-mei(Department of Medical Laboratory,Shanxi Cancer Hospital,Taiyuan 030013,China)
FAN Ning-fang(Department of Medical Laboratory,Shanxi Cancer Hospital,Taiyuan 030013,China)
FENG Yu-jiao(Department of Medical Laboratory,Shanxi Cancer Hospital,Taiyuan 030013,China)
KANG Yan(Department of Medical Laboratory,Shanxi Cancer Hospital,Taiyuan 030013,China)
Journal Title:
Cancer Research and Clinic
Issue:
Volume 24, Issue 08, 2012
DOI:
10.3760/cma.j.issn.1006-9801.2012.08.015
Key Word:
Colorectal neoplasms; Homocysteine; Enzymatic circling assay

Abstract: Objective To investigate the changes of serum homocysteine (Hcy) level before and after treatment in patients with colorectal cancer,and provide the reference for clinical therapeutic efficacy and prognosis.Methods Enzymatic circling assay was used to measure the serum Hcy levels in 50 controls and 58 patients with colorectal cancer before and after treatment with a.follow-up of 12 months.The changes of Hcy aud the relationship between Hcy and therapeutic efficacy or prognosis were analyzed.Results Scrum Hcy level in patients with colorectal cancer was significantly higher than that in controls [(16.90±5.35) μmol/L vs (10.23±3.06) μmol/L] (P < 0.01),and it was closely associated with TNM stage.Serum Hcy level in patients of stage Ⅲ-Ⅳ was significantly higher than that of stage Ⅰ-Ⅱ [(18.49±5.13) μmol/L vs (15.20±4.86) μmol/L] (P < 0.05).The Hcy level in patients at the end of treatment was significantly lower than that before treatment [(13.39±4.98) μmol/L vs (16.90±5.35) μmol/L] (P < 0.01),and the Hcy level after the treatment for 3 month was significantly lower than that at the end of treatment [(10.23±3.17) μmol/L] (P < 0.05).The Hcy level in patients with recurrence during 12 months after operation was significantly higher than that without recurrence [(17.18±4.82) μmol/L vs (12.36±3.19) μmol/L] (P < 0.01).Conclusion Serum level of Hcy might be a useful marker for predicting therapeutic efficacy and prognosis in patients with colorectal cancer.

  • [1]Kohaar I,Kumar J,Thakur N,et el.Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population.Biomarkers,2010,15:61-68.
  • [2]Wu LL,Wu JT.Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor markers.Clin Chim Acta,2002,322:21-28.
  • [3]Uivik A,Vollset SE,Hansen S,et al.Colorectal cancer and the methylene tetrahydrofolate reductase 677C-T and methionine 2756 A-G polymorphisms:a study of 2168 case-control pairs from the JANUS cohort.Cancer Epidemiol Biomarkers Prev,2004,13:2175-2180.
  • [4]Wei Q,Shen H,Wang LE,et al.Assosiation between low dietary folate intake and suboptimal cellular DNA repair capacity.Cancer Epidemiol Biomarkers Prey,2003,12:963-969.
  • [5]Sun CF,Haven TR,Wu TL,et al.Serum total homocysteine increases with the rapid proliferation rate of tumor cells and decline upon cell death:a potential new tumor marker.Clin Chim Acta,2002,321:55-62.
  • [6]Eussen SJ,Vollset SE,Igland J,et al.Plasma folate,related genetic variants,and colorectal cancer risk in EPIC.Cancer Epidemiol Biomarkers Prey,2010,19:1328-1340.
  • [7]Eussen SJ,Vollset SE,Hustad S,et al.Plasma vitamins B2,B6,and B12,and related genetic variants as predictors of colorectal cancer risk.Cancer Epidemiol Biomarkers Prey,2010,19:2549-2561.
  • [8]何炳虹,陈光辉,潘引鹏.食管癌患者手术前后血清HCY、IGF-Ⅱ 和TSGF检测的临床意义.放射免疫学杂志,2010,23:491-492.
  • [9]刘梦琼,潘虹,王俏梅,等.宫颈癌患者治疗前、后血清同型半胱氨酸浓度变化的研究.检验医学,2011,26:436-439.
  • [10]汪瑞,周军,沈俊.乳腺癌手术前后检测CA153、HCY和VEGF的临床意义.中国肿瘤外科杂志,2011,3:341-343.
  • [11]陈耀平,王宁菊,杨宝珍.同型半胱氨酸对人乳腺癌患者外周血单核细胞TF和uPA及uPAR表达的影响.中华肿瘤防治杂志,2009,16:772-774.
  • [12]朱凡,王毓明,朱勤英.血浆同型半胱氨酸、血清叶酸及亚甲基四氢叶酸还原酶基因多态性与结直肠癌发病关系的研究.东南大学学报:医学版,2010,29:88-92.
  • [13]Ferroni P,Palmirotta R,Martini F,et al.Determinants of homocysteine levels in colorectal and breast cancer patients.Anticancer Res,2009,29:4131-4138.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn